Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
DiBenedetti DB, Coles TM, Sharma T, Pericleous L. Patients' and caregivers' perspectives on stability of factor viii products for hemophilia a: a web-based study in the United States and Canada. Presented at the 65th Annual International Meeting, National Hemophilia Foundation; October 2013. Anaheim, CA.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective study of plasma-derived factor VIII/vWF in immune tolerance induction therapy: the SPIRIT registry. Poster presented at the Annual Meeting of the National Hemophilia Foundation; October 2013.
DiBenedetti D, Coles T, Ling CS, Sharma T, Pericleous L. Web-based study of patients and caregivers in the United States and Canada: perspectives on improvements in stability of factor viii products for hemophilia a. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):A121.
DiBenedetti D, Coles T, Sharma T. Recruiting patients with a rare blood disorder and their caregivers through social media. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 May; 16(3):A51.
Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2013 Feb 1;22(2):111-21.